{"id":"dfcdcd70da50","type":"article","url":"https://hartvaat.nl/2024/10/21/shensong-yangxin-voorkomt-af-recidief-na-ablatie-bij-persisterend-af/","title":"Shensong Yangxin voorkomt AF-recidief na ablatie bij persisterend AF","title_en":"Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehae532","source_url":"https://doi.org/10.1093/eurheartj/ehae532","authors":["He Huang","Yu Liu","Wei Shuai","Chenyang Jiang","Menghe Zhang","Xiufen Qu","Wenqing Zheng","Hao Yang","Fan Liu","Bo Yu","Manhua Chen","Bin Mu","Chen Yao","Yanhong Tang","Congxin Huang","Feifan Ouyang","Zhenhua Jia"],"significance":6,"published":"2024-10-21","source_date":"2024-10-21","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/ritmecontrole-af/","https://hartvaat.nl/kennis/antistolling/antistolling-bij-ckd/"],"congress":"","summary_en":"This randomized trial showed that Shensong Yangxin, a traditional Chinese medicine, reduces AF recurrence after ablation for persistent AF, providing randomized evidence for an herbal anti-arrhythmic approach.","created":"2026-07-03T10:31:15Z","updated":"2026-07-03T13:30:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Gerandomiseerde trial toonde dat het traditionele Chinese geneesmiddel Shensong Yangxin het AF-recidief na ablatie voor persisterend AF vermindert. De anti-aritmische werking vereist bevestiging in internationale studies.","abstract_original":"BACKGROUND AND AIMS: Despite advances in technology and techniques, the recurrence rate of persistent atrial fibrillation (AF) following catheter ablation remains high. The Shensong Yangxin (SSYX) capsule, a renowned traditional Chinese medicine formula, is used in the treatment of cardiac arrhythmias. This trial aimed to investigate whether the SSYX can improve clinical outcomes in patients who have undergone catheter ablation for persistent AF. METHODS: A multi-centre, randomized, double-blind, placebo-controlled clinical trial was conducted at 66 centres in China among 920 patients with persistent AF undergoing first ablation. Participants were randomized to oral SSYX, 1.6 g (.4 g/granule) thrice daily (n = 460), or matched placebo (n = 460) for 12 months. The primary endpoint was recurrent atrial tachyarrhythmias lasting for ≥30 s following a blanking period of 3 months. Secondary endpoints included time to first documented atrial tachyarrhythmias, AF burden, cardioversion, stroke/systemic embolism, changes in echocardiographic parameters, and quality-of-life (QoL) score. Analyses were performed according to the intention-to-treat principle. RESULTS: A total of 920 patients underwent randomization (460 assigned to SSYX group and 460 assigned to placebo group). During the follow-up of 12 months, patients assigned to SSYX had a higher event-free rate from recurrent atrial tachyarrhythmias when compared with the placebo group (12-month Kaplan-Meier event-free rate estimates, 85.5% and 77.7%, respectively; hazard ratio, .6; 95% confidence interval .4-.8; P = .001). Patients assigned to receive SSYX had a better QoL score at 12 months compared to those randomized to placebo. There was no significant difference in the incidence of serious adverse events between the two groups. CONCLUSIONS: Treatment with SSYX following radiofrequency catheter ablation for persistent AF reduced the incidence of recurrent atrial tachyarrhythmias and led to clinically significant improvements in QoL during a 12-month follow-up in a Chinese population."}